In an infant with pseudohypoaldosteronism type I (1978) reported that the latter disorder is amenable to treatment with indomethacin, a potent inhibitor of prostaglandin synthesis. Therefore, these authors assumed that the production of the saluretic renal prostaglandins might be increased. In the pre¬ sent study urinary prostaglandin excretion was measured in an in¬ fant with the typical features of pseudohypoaldosteronism type I.
(6.15 ng/mg creatinine; normal mean \m=+-\ SE: 2.93 \ m=+-\ 0.91) was found. Prostaglandin excretion as well as the typical hyperkalemia, hyperreninemia and hyperaldosteronism normalized with adequate dietary salt supplementation. An abnormally high excretion of the renal prostaglandins was again present at age 4.4 years when the child was thriving although additional salt was withheld. These abnormalities are considered to be secondary to this condition's basic defect which remains to be elucidated.
Pseudohypoaldosteronism was first described by Cheek and Perry (1958) as a rare cause of salt loss in infancy. Salt wasting oc¬ curs despite high levels of plasma renin activity and aldosterone (Dillon et al. 1980) . Several Schambelan et al. (1981) in distinction to the more common condition of infantile onset designated as type I. Rampini et al. (1978) reported that the latter disorder is amenable to treatment with indomethacin, a potent inhibitor of prostaglandin synthesis. Therefore, these authors assumed that the production of the saluretic renal prostaglandins might be increased. In Usberti et al. 1985) . Exces¬ sive renal prostaglandin synthesis may not be looked upon as the primary defect. Evidence has been presented that pseudohypoaldoste¬ ronism is due to a defect in sodium reabsorption in the proximal re¬ nal tubules (Postel-Vlnay et al. 1974) . The salt wasting is asso- 
